bioRxivCancer BiologyPreprint
KMT2C deficiency promotes APOBEC mutagenesis and genomic instability in multiple cancers
Abstract
Histone methyltransferase KMT2C is among the frequently mutated epigenetic modifier genes in cancer. It has additional roles in DNA replication, but the effects of KMT2C deficiency on genomic instability during tumorigenesis are unclear. Analyzing 9,663 tumors from 30 cohorts, we report that KMT2C mutant tumors have a significant excess of APOBEC mutational signatures in several cancer types. We show that KMT2C deficiency promotes APOBEC expression and deaminase activity, and compromises DNA replication speed and delays fork restart, facilitating APOBEC mutagenesis targeting ssDNA near stalled forks. APOBEC-mediated mutations primarily accumulate during early replication, and tend to cluster along the genome and also in 3D nuclear contexts. Excessive APOBEC mutational signatures in KMT2C mutant tumors correlate with elevated genomic instability and signatures of homologous recombination deficiency. We propose that in multiple cancer types KMT2C deficiency is a likely driver of APOBEC mutagenesis, which promotes further genomic instability during cancer progression.
- organism: human
- assay: whole-genome sequencing
- research focus: chromatin & epigenetic regulation
- research focus: cancer & tumor microenvironment
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DNMT1-Mediated Epigenetic Reprogramming Drives KMT2A Amplifications and Rearrangements
Madison A. Lineberger, Zach H. Gray, … Johnathan R. Whetstine·bioRxiv·Sep 22, 2026
- Genetic modifiers of APOBEC-induced mutagenesis
Tony M. Mertz, Elizabeth Rice-Reynolds, … Steven A. Roberts·Genome ResearchPeer-reviewed·Sep 1, 2023
- The APOBEC3A deaminase drives episodic mutagenesis in cancer cells
M. Petljak, K. Chu, … J. Maciejowski·bioRxiv·Feb 14, 2021
- Metallothionein loss in cancer cells contributes to increased mutations through defective DNA repair and metabolic imbalance
Mirna Mina-Abouda, Amy C. Rees, … Joe Ryan Delaney·bioRxiv·Aug 12, 2026
- Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of lysine demethylation and oxidative phosphorylation
S. S. Dhar, C. Brown, … M. Lee·bioRxiv·Oct 29, 2023
- Deficiency in DNA mismatch repair of methylation damage is a major mutational process in cancer
Fang Hu, Xiaoqiang Zhu, … Jason W.H. Wong·bioRxiv·Nov 18, 2020